The 'Bone-Brain' Crosstalk Mechanism of Subchondral Bone Nociceptive Sensitization Activating SPP1-Positive Microglia in the vlPAG Region Elucidates the Theoretical Connotation of Treating Knee Osteoarthritis Based on Kidney Differentiation

ConditionOsteoarthitis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age60-70
SponsorJinchao Xu

About this trial

The aim of this observational study is to investigate the relationship between pain severity and alterations in bone-derived and brain-derived signaling molecules (including serum neurotransmitters and inflammatory cytokines), as well as structural and functional changes in the ventrolateral periaqueductal gray (vlPAG) region in patients with kidney-deficiency type knee osteoarthritis (KOA). The central question it seeks to address is whether changes in these signaling molecules and vlPAG alterations are associated with the degree of pain.

Patients scheduled to undergo total knee arthroplasty (TKA) due to KOA will be enrolled prior to surgery. Before the operation, they will undergo questionnaire assessments, physical examinations, imaging evaluations, and blood sample collection. The resected tibial plateau tissue obtained during surgery will be used for subsequent laboratory analyses.

Eligibility criteria

Qualifiers

Clinical diagnosis of KOA

Age between 60-70 years.

Kellgren-Lawrence grade IV on anteroposterior and lateral knee X-rays.

Scheduled for total knee arthroplasty.

Disqualifiers

Clinical diagnosis of ankylosing spondylitis, rheumatoid arthritis, gout, or other related conditions.

Presence of metabolic bone diseases, acute trauma, malignancies, infections, or other complications severely affecting knee function.

Use of drugs affecting bone metabolism (e.g., corticosteroids, zoledronic acid) within the past 6 months.

Presence of psychiatric disorders or serious cardiovascular, pulmonary, renal, hepatic, hematologic, or other systemic diseases.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

120 Participants
are grouped into 2 trial groups

Locations

This trial has no locations

Sponsors and collaborators

Jinchao Xu

Lead sponsor

Fujian University of Traditional Chinese Medicine

Sponsor institution